FDA

In a divided two-day meeting, the Pharmacy Compounding Advisory Committee supported BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, while rejecting Emideltide. The votes do not approve the peptides or immediately authorize their use in patient-specific pharmacy compounding.

Oral versus injectable, local versus systemic, short cycle versus long — BPC-157 has some of the most elaborate community conventions of any peptide, built almost entirely on animal data and repetition rather than human trials.

In a single day, the FDA told multiple peptide sellers that an RUO label does not control when the surrounding evidence establishes an intended human-drug use. The reasoning is worth reading closely.